{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:30:35Z","timestamp":1793813435078,"version":"4.6.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jhepr.2026.101993","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:54:42Z","timestamp":1786492482000},"page":"101993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2\/F3 fibrosis: An analysis of ESSENCE"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2010-8284","authenticated-orcid":false,"given":"Margarida","family":"Augusto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-1125","authenticated-orcid":false,"given":"Robert","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4107-4818","authenticated-orcid":false,"given":"Aslak Sindbjerg","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotis","family":"Tefos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6131-3981","authenticated-orcid":false,"given":"Michelle","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101993_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhepr.2026.101993_bib2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101993_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"The Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101993_bib4","series-title":"FDA approves treatment for serious liver disease known as \u2018MASH\u2019","year":"2025"},{"key":"10.1016\/j.jhepr.2026.101993_bib5","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101993_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1477-7525-7-27","article-title":"Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?","volume":"7","author":"Rowen","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jhepr.2026.101993_bib7","series-title":"ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials","year":"2020"},{"key":"10.1016\/j.jhepr.2026.101993_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13696998.2022.2026702","article-title":"Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease","volume":"25","author":"Rustgi","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.jhepr.2026.101993_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100642","article-title":"Assessments of health utilities in patients with metabolic dysfunction-associated steatohepatitis: cross-walk between disease-specific chronic liver disease Questionnaire, Short form SF-6D, and EuroQol EQ-5D instruments","volume":"4","author":"Younossi","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.jhepr.2026.101993_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-publhealth-052120-012811","article-title":"Health-related quality of life measurement in public health","volume":"43","author":"Kaplan","year":"2022","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.jhepr.2026.101993_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12955-023-02195-x","article-title":"Cross-walk of the chronic liver disease Questionnaire for nonalcoholic steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH","volume":"21","author":"Fishman","year":"2023","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jhepr.2026.101993_bib13","series-title":"Estimating EQ-5D by age and sex for the UK. Report by the decision support unit","year":"2022"},{"key":"10.1016\/j.jhepr.2026.101993_bib11","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/dom.15090","article-title":"The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials","volume":"25","author":"Bjorner","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:40:25Z","timestamp":1793810425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589555926002648"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101993","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EQ-5D health utility gains with once-weekly semaglutide 2.4 mg in people with MASH and F2\/F3 fibrosis: An analysis of ESSENCE","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101993"}}